Adjuvant Pemetrexed Plus Cisplatin: A Safer Option for Non-Squamous NSCLC?

The study evaluated the efficacy and tolerability of adjuvant treatment with pemetrexed/cisplatin vs  vinorelbine/cisplatin in patients with non-squamous NSCLC.

Source: CancerNetwork - June 2, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news